
==== Front
Adv TherAdv TherAdvances in Therapy0741-238X1865-8652Springer Healthcare Cheshire 53810.1007/s12325-017-0538-3ErratumErratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries Gulácsi László laszlo.gulacsi@uni-corvinus.hu 1Brodszky Valentin 1Baji Petra 1Rencz Fanni 1Péntek Márta 121 0000 0000 9234 5858grid.17127.32Corvinus University of Budapest and HTA Consulting Budapest, Budapest, Hungary 2 Flór Ferenc County Hospital, Kistarcsa, Hungary 26 4 2017 26 4 2017 2017 34 5 1234 1234 © The Author(s) 2017issue-copyright-statement© Springer Healthcare 2017
==== Body
Erratum to: Adv Ther DOI 10.1007/s12325-017-0522-y
The authors of this manuscript have noticed a mistake since publication of their manuscript.

In the original publication, the “Total RTX consumption per patient (mg)” in Table 1, was incorrectly published as 1814.00. The correct value of “Total RTX consumption per patient (mg)” should read as 11,814.00.


The online version of the original article can be found under doi:10.1007/s12325-017-0522-y.

Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
